Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Shares Issued (2016 - 2025)

Perspective Therapeutics' Shares Issued history spans 15 years, with the latest figure at $371000.0 for Q3 2025.

  • For Q3 2025, Shares Issued rose 18450.0% year-over-year to $371000.0; the TTM value through Sep 2025 reached $276.1 million, up 52481.52%, while the annual FY2024 figure was $275.8 million, N/A changed from the prior year.
  • Shares Issued for Q3 2025 was $371000.0 at Perspective Therapeutics, down from $275.7 million in the prior quarter.
  • Across five years, Shares Issued topped out at $275.7 million in Q4 2024 and bottomed at -$291000.0 in Q2 2022.
  • The 5-year median for Shares Issued is $42000.0 (2022), against an average of $23.7 million.
  • The largest annual shift saw Shares Issued plummeted 99.28% in 2022 before it skyrocketed 68820.5% in 2024.
  • A 5-year view of Shares Issued shows it stood at -$28000.0 in 2021, then changed by 0.0% to -$28000.0 in 2022, then surged by 1528.57% to $400000.0 in 2023, then surged by 68820.5% to $275.7 million in 2024, then plummeted by 99.87% to $371000.0 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Shares Issued are $371000.0 (Q3 2025), $275.7 million (Q4 2024), and $2000.0 (Q3 2024).